The Covid-19 vaccine developed by China's Sinopharm has been approved for emergency use in the Maldives, the Maldives Food and Drug Administration (MFDA) announced at a press conference on Monday.
The vaccine made by China National Pharmaceutical Group (Sinopharm) will be given to people aged between 18 and 60, local media reported, citing an official at the MFDA. The MFDA also announced that the vaccine made by Pfizer has also been approved for emergency use, the Xinhua news agency reported.
The Covishield vaccine based on a formula by AstraZeneca and Oxford University and manufactured by the Serum Institute of India was approved for emergency use in late January.
The government of Maldives has been vaccinating its population against the pandemic since February 1, prioritising frontline health workers and other high-risk groups. Vaccinations are available free of charge to residents over the age of 18, including undocumented immigrants.
According to the statistics from the Health Protection Agency (HPA), 206,114 people have been vaccinated as of Sunday. Meanwhile, the total number of confirmed cases of Covid-19 in the Maldives has reached 21,572, including 64 deaths.
--IANS
int/rs
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU